Zobrazeno 11 - 20
of 52
pro vyhledávání: '"Pedro R. Lowenstein"'
Autor:
Stephen Carney, Andrea Comba, Maria B. Garcia-Fabiani, Alejandro Javier Nicola Candia, Ava Mauser, Anna Schwendeman, Maria Ventosa, Marianela Candolfi, Lindsay Scheetz, Pedro R. Lowenstein, Mahmoud S. Alghamri, Padma Kadiyala, James J. Moon, Joerg Lahann, Maria G. Castro, Syed M Faisal
Publikováno v:
CONICET Digital (CONICET)
Consejo Nacional de Investigaciones Científicas y Técnicas
instacron:CONICET
Consejo Nacional de Investigaciones Científicas y Técnicas
instacron:CONICET
Gliomas are infiltrating brain tumors associated with high morbidity and mortality. Current standard of care includes radiation, chemotherapy and surgical resection. Today, survival rates for malignant glioma patients remain dismal and unchanged for
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::feb1626dafe0a01d701a6f662b67b397
https://www.tandfonline.com/doi/full/10.1080/13543784.2020.1768528
https://www.tandfonline.com/doi/full/10.1080/13543784.2020.1768528
Autor:
Alireza Hassani Najafabadi, Xiaoqi Sun, Sejin Son, Padma Kadiyala, Lindsay Scheetz, Anna Schwendeman, Pedro R. Lowenstein, James J. Moon, Marisa E. Aikins, Maria G. Castro
Publikováno v:
Clin Cancer Res
Purpose: Gliomas are brain tumors with dismal prognoses. The standard-of-care treatments for gliomas include surgical resection, radiation, and temozolomide administration; however, they have been ineffective in providing significant increases in med
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1e8903c868986a6447b69e26304c9f23
https://europepmc.org/articles/PMC7442596/
https://europepmc.org/articles/PMC7442596/
Autor:
Marianela Candolfi, Mahmoud S. Alghamri, David B. Altshuler, Maria G. Castro, Felipe J Nunez, Padma Kadiyala, Antonela Sofía Asad, Stephen Carney, Anna Schwendeman, Joerg Lahann, Alejandro Javier Nicola Candia, Fernando M. Nunez, Pedro R. Lowenstein, James J. Moon, Maria B. Garcia-Fabiani
Publikováno v:
Expert Opin Biol Ther
Introduction: The field of neuro-oncology has experienced significant advances in recent years. More is known now about the molecular and genetic characteristics of glioma than ever before. This knowledge leads to the understanding of glioma biology
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::84060f4e081cdde6482b43f3709cfb06
https://europepmc.org/articles/PMC7059118/
https://europepmc.org/articles/PMC7059118/
Autor:
Mahmoud S. Alghamri, Felipe J Nunez, Maria G. Castro, Neha Kamran, Pedro R. Lowenstein, David Altshuler, Stephen Carney
Publikováno v:
Methods Enzymol
Glioma is one of the most aggressive tumors. The median survival of the most aggressive form (Glioblastoma (GBM)) is approximately 14–20 months. The current standard of care includes tumor resection, chemotherapy and radiation, nevertheless, the in
Publikováno v:
Clinical Immunology. 189:34-42
Various preclinical studies have demonstrated that the success of immunotherapeutic strategies in inhibiting tumor progression in animal models of Glioblastoma multiforme (GBM). It is also evident that tumor-induced immune suppression drastically imp
Autor:
Meghna Saxena, Pedro R. Lowenstein, Youping Li, Maria G. Castro, Neha Kamran, Nicholas Raja, Padma Kadiyala, Diana Shah, Mariela A. Moreno-Ayala, Marianela Candolfi
Publikováno v:
CONICET Digital (CONICET)
Consejo Nacional de Investigaciones Científicas y Técnicas
instacron:CONICET
Consejo Nacional de Investigaciones Científicas y Técnicas
instacron:CONICET
Survival of glioma (GBM) patients treated with the current standard of care remains dismal. Immunotherapeutic approaches that harness the cytotoxic and memory potential of the host immune system have shown great benefit in other cancers. GBMs have de
Autor:
Anna Schwendeman, Lindsay Scheetz, Kyung Soo Park, Pedro R. Lowenstein, James J. Moon, Qiao Li, Maria G. Castro
Publikováno v:
Nat Biomed Eng
Research into the immunological processes implicated in cancer has yielded a basis for the range of immunotherapies that are now considered the fourth pillar of cancer treatment (alongside surgery, radiotherapy and chemotherapy). For some aggressive
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::94f04d5684bf579243eb45632a6d085e
https://europepmc.org/articles/PMC6783331/
https://europepmc.org/articles/PMC6783331/
High-Density Lipoprotein-Mimicking Nanodiscs for Chemo-immunotherapy against Glioblastoma Multiforme
Autor:
Maria G. Castro, Padma Kadiyala, Robert Doherty, Minzhi Yu, Neha Kamran, David Altshuler, Dan Li, Rui Kuai, Pedro R. Lowenstein, James J. Moon, Marta Edwards, Fernando M. Nunez, Anna Schwendeman
Publikováno v:
ACS Nano.
Glioblastoma multiforme (GBM) is an aggressive primary brain tumor, for which there is no cure. Treatment effectiveness for GBM has been limited due to tumor heterogeneity, an immunosuppressive tumor microenvironment (TME) and the presence of the blo
Autor:
Felipe J Nunez, Mahmoud S. Alghamri, Maria G. Castro, Neha Kamran, Ruthvik Avvari, Padma Kadiyala, Pedro R. Lowenstein, Li Zhang
Molecular characterization studies have illustrated that mutation in isocitrate dehydrogenase (mIDH1) enzyme, which is present in most patients with low grade glioma (LGG) and secondary glioma is correlated with better prognosis and survival [1]. We
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8234ca6df2b355d5337e664ca2f23825
https://europepmc.org/articles/PMC6216656/
https://europepmc.org/articles/PMC6216656/
Autor:
Maria G. Castro, Pedro R. Lowenstein, Yohei Mineharu, Gregory J. Baker, Anda Alexandra Calinescu, Neha Kamran
Publikováno v:
Immunotherapy. 7:1073-1104
In the last decade, numerous studies of immunotherapy for malignant glioma (glioblastoma multiforme) have brought new knowledge and new hope for improving the prognosis of this incurable disease. Some clinical trials have reached Phase III, following